Subthalamic Nucleus Deep Brain Stimulation in Speech Study

Description

Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) have unpredictable and varied speech outcomes after this treatment. Our research will prospectively document speech performance before, during and 6- and 12-months after STN-DBS in 80 surgically treated patients and compared with 40 non-surgical controls with Parkinson's disease. This study will provide unique insights into the role of STN in speech production, document speech outcome in a comprehensive fashion, identify factors that predict functional communication ability 12 months after STN-DBS, and test the feasibility of low frequency DBS in reversing DBS-induced speech declines in order to optimize treatment strategies for those living with Parkinson's disease.

Conditions

Parkinson Disease, Dysarthria

Talk to us

Study Overview

On this page

Study Details

Study overview

Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN) have unpredictable and varied speech outcomes after this treatment. Our research will prospectively document speech performance before, during and 6- and 12-months after STN-DBS in 80 surgically treated patients and compared with 40 non-surgical controls with Parkinson's disease. This study will provide unique insights into the role of STN in speech production, document speech outcome in a comprehensive fashion, identify factors that predict functional communication ability 12 months after STN-DBS, and test the feasibility of low frequency DBS in reversing DBS-induced speech declines in order to optimize treatment strategies for those living with Parkinson's disease.

Role of Subthalamic Nucleus in Speech and Movement Among People With Parkinson's Disease as Revealed by Intraoperative Recordings and Deep Brain Stimulation

Subthalamic Nucleus Deep Brain Stimulation in Speech Study

Condition
Parkinson Disease
Intervention / Treatment

-

Contacts and Locations

Iowa City

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States, 52242

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * have a confirmed diagnosis of idiopathic Parkinson's disease and no atypical Parkinsonism features
  • * experience significant motor fluctuations
  • * currently taking and responsive to dopaminergic medications (e.g. Levodopa)
  • * use English as their primary language
  • * lack significant cognitive impairment and be able to consent to participate
  • * Significant hearing loss/reliance on hearing aids

Ages Eligible for Study

21 Years to 84 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jeremy Greenlee,

Jeremy Greenlee, MD, PRINCIPAL_INVESTIGATOR, University of Iowa Dept of Neurosurgery

Study Record Dates

2025-07